ISRCTN61336225.

Methods	Prospective double‐blind placebo controlled trial
Participants	Children diagnosed as asthmatic according to The Global Initiative for Asthma (GINA) guidelines, aged 5 to 14 years old, capable of measuring PEFR, presenting with moderate to severe acute exacerbation according to paediatric asthma severity score and PEFR
Interventions	Group A: participants receive inhaled salbutamol solution (0.15 mL/kg) plus isotonic magnesium sulfate (2 mL) in a nebulizer chamber; Group B: participants receive inhaled salbutamol solution (0.15 mL/kg), diluted with placebo (normal saline 2 mL) in a nebulizer chamber.
Outcomes	1. Asthma severity measured using the Pediatric Asthma Severity Score (PASS) at baseline, 20, 40 and 60 minutes post‐nebulisation 2. Oxygen saturation measured using pulse oximetry at baseline, 20, 40 and 60 minutes post‐nebulisation 3. Lung function assessed through measuring peak expiratory flow rate (PEFR) at baseline, 20, 40 and 60 minutes post‐nebulisation
Notes	Trial stated as complete February 2016 but no associated publication identified. Contact person emailed on 7 September 2017 to enquire about status of results/publication. No response received at time of review publication.